Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11311544

Treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11304916

Methods and compositions for the treatment of Shiga Toxicosis

The Board of Regents of the University of Texas System · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11305002

Compositions and treatments for Haemophilus influenzae

The Board of Regents of the University of Oklahoma · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11299751

Compositions for the treatment of disease

VOYAGER THERAPEUTICS, INC. · Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11299492

JAK kinase inhibitor compounds for treatment of respiratory disease

Theravance Biopharma R&D IP, LLC · Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11298441

Biodegradable biomimetics of growth plate cartilage for the treatment of physeal injuries

The Regents of the University of Colorado, a Body Corporate · Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11291659

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Fulcrum Therapeutics, Inc. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11291658

Use of gaboxadol in the treatment of diabetes and related conditions

OVID THERAPEUTICS INC. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11292842

Anti-PD-1 antibodies for treatment of lung cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11285194

Combination immunotherapy approach for treatment of cancer

Calidi Biotherapeutics, Inc. · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11285139

Treatment of CNS conditions

Takeda Pharmaceutical Company Limited · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11285129

Treatment of circadian rhythm disorders

VANDA PHARMACEUTICALS INC. · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11279933

Antisense oligonucleotides for the treatment of leber congenital amaurosis

Stichting Radboud universitair medisch centrum · Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11278632

Engineered nucleases useful for treatment of hemophilia A

Precision BioSciences, Inc. · Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11273226

Hydrogel prodrug for treatment

Viking Scientific, Inc. · Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11273150

Compositions and methods for the treatment of presbyopia

Lenz Therapeutics, Inc. · Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11266622

Method of treatment

VANDA PHARMACEUTICALS INC. · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11266726

Compositions and methods for the treatment of HER2-expressing solid tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11266746

Therapeutic antitumor combination of a TLR4 ligand with other treatments

The United Slates of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11266724

Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Catalyst Biosciences, Inc. · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11268077

Materials and methods for treatment of hemoglobinopathies

Vertex Pharmaceuticals Incorporated · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11268154

Methods for the identification, evaluation and treatment of patients having multiple myelo

Takeda Pharmaceutical Company Limited · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11260050

Combination of cotinine plus antioxidant for treatment-resistant depression and correction

United States Government as represented by the Department of Veterans Affairs · Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11253509

Methods of treatment for cystic fibrosis

Vertex Pharmaceuticals Incorporated · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted